Role of oxidative stress and the microenvironment in breast cancer development and progression

Advances in Cancer Research

Volumn 119, Issue , 2013, Pages 107-125

  Jezierska Drutel, Agnieszka ^a   Rosenzweig, Steven A ^a   Neumann, Carola A ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breast cancer; Cancer associated fibroblasts; Microenvironment; Myofibroblasts; Oxidative stress; Reactive oxygen species; Stroma associated fibroblasts

Indexed keywords

ACETYLCYSTEINE; ALPHA SMOOTH MUSCLE ACTIN; ANTINEOPLASTIC AGENT; CALPONIN; CATHEPSIN B; CELL SURFACE MARKER; COLLAGEN TYPE 1; DESMIN; ENDOSIALIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST ACTIVATION PROTEIN; FIBROBLAST SPECIFIC PROTEIN; GELATINASE A; GELATINASE B; HYDROGEN PEROXIDE; METFORMIN; MONOCARBOXYLATE TRANSPORTER 4; PROCOLLAGEN; PROSTAGLANDIN SYNTHASE; QUERCETIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SACCHAROPINE DEHYDROGENASE; STROMELYSIN; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIMENTIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CARCINOGENICITY; CELL AGING; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CHEMOSENSITIVITY; ENERGY METABOLISM; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; MYOFIBROBLAST; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN METABOLISM; RISK FACTOR; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT;

EID: 84880430327     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407190-2.00003-4     Document Type: Chapter

References (80)

1. Balliet R.M., Capparelli C., Guido C., Pestell T.G., Martinez-Outschoorn U.E., Lin Z., et al. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: Understanding the aging and cancer connection. Cell Cycle 2011, 10:4065-4073.
2. Bardeesy N., Aguirre A.J., Chu G.C., Cheng K.H., Lopez L.V., Hezel A.F., et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:5947-5952.
3. Basuroy S., Bhattacharya S., Leffler C.W., Parfenova H. Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. American Journal of Physiology. Cell Physiology 2009, 296:C422-C432.
4. Boidot R., Vegran F., Meulle A., Le Breton A., Dessy C., Sonveaux P., et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Research 2012, 72:939-948.
5. Campisi J. Aging, cellular senescence, and cancer. Annual Review of Physiology 2013, 75:685-705.
6. Canter J.A., Kallianpur A.R., Parl F.F., Millikan R.C. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Research 2005, 65:8028-8033.
7. Cao J., Schulte J., Knight A., Leslie N.R., Zagozdzon A., Bronson R., et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. The EMBO Journal 2009, 28:1505-1517.
8. Capparelli C., Chiavarina B., Whitaker-Menezes D., Pestell T.G., Pestell R.G., Hulit J., et al. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012, 11:3599-3610.
9. Capparelli C., Guido C., Whitaker-Menezes D., Bonuccelli G., Balliet R., Pestell T.G., et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle 2012, 11:2285-2302.
10. Capparelli C., Whitaker-Menezes D., Guido C., Balliet R., Pestell T.G., Howell A., et al. CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 2012, 11:2272-2284.
11. Chiavarina B., Whitaker-Menezes D., Migneco G., Martinez-Outschoorn U.E., Pavlides S., Howell A., et al. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle 2010, 9:3534-3551.
12. Comito G., Giannoni E., Di Gennaro P., Segura C.P., Gerlini G., Chiarugi P. Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness. Cancer Letters 2012, 324:31-41.
13. Coppe J.P., Patil C.K., Rodier F., Krtolica A., Beausejour C.M., Parrinello S., et al. A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One 2010, 5:e9188.
14. Czarnecka A.M., Krawczyk T., Zdrozny M., Lubinski J., Arnold R.S., Kukwa W., et al. Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. Breast Cancer Research and Treatment 2010, 121:511-518.
15. Edderkaoui M., Nitsche C., Zheng L., Pandol S.J., Gukovsky I., Gukovskaya A.S. NADPH oxidase activation in pancreatic cancer cells is mediated through Akt-dependent up-regulation of p22phox. The Journal of Biological Chemistry 2011, 286:7779-7787.
16. Felty Q. Redox sensitive Pyk2 as a target for therapeutics in breast cancer. Frontiers in Bioscience 2011, 16:568-577.
17. Fu X., Kassim S.Y., Parks W.C., Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. The Journal of Biological Chemistry 2001, 276:41279-41287.
18. Fujiwara Y., Sugita Y., Nakamori S., Miyamoto A., Shiozaki K., Nagano H., et al. Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. International Journal of Oncology 2000, 16:799-804.
19. Goh J., Enns L., Fatemie S., Hopkins H., Morton J., Pettan-Brewer C., et al. Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer 2011, 11:191.
20. Gonzalez-Angulo A.M., Ferrer-Lozano J., Stemke-Hale K., Sahin A., Liu S., Barrera J.A., et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Molecular Cancer Therapeutics 2011, 10:1093-1101.
21. Graham K.A., Kulawiec M., Owens K.M., Li X., Desouki M.M., Chandra D., et al. NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biology & Therapy 2010, 10:223-231.
22. Haviv I., Polyak K., Qiu W., Hu M., Campbell I. Origin of carcinoma associated fibroblasts. Cell Cycle 2009, 8:589-595.
23. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nature Medicine 2009, 15:1077-1081.
24. Heering J., Erlmann P., Olayioye M.A. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Experimental Cell Research 2009, 315:2505-2514.
25. Hiscox S., Barrett-Lee P., Nicholson R.I. Therapeutic targeting of tumor-stroma interactions. Expert Opinion on Therapeutic Targets 2011, 15:609-621.
26. Hyoudou K., Nishikawa M., Kobayashi Y., Ikemura M., Yamashita F., Hashida M. SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clinical & Experimental Metastasis 2008, 25:531-536.
27. Jensen J.D., Knoop A., Laenkholm A.V., Grauslund M., Jensen M.B., Santoni-Rugiu E., et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Annals of Oncology 2012, 23:2034-2042.
28. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nature Reviews. Cancer 2006, 6:392-401.
29. Kankuri E., Babusikova O., Hlubinova K., Salmenpera P., Boccaccio C., Lubitz W., et al. Fibroblast nemosis arrests growth and induces differentiation of human leukemia cells. International Journal of Cancer 2008, 122:1243-1252.
30. Kankuri E., Cholujova D., Comajova M., Vaheri A., Bizik J. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Research 2005, 65:9914-9922.
31. Kim H.S., Patel K., Muldoon-Jacobs K., Bisht K.S., Aykin-Burns N., Pennington J.D., et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17:41-52.
32. Koch S., Volkmar C.M., Kolb-Bachofen V., Korth H.G., Kirsch M., Horn A.H., et al. A new redox-dependent mechanism of MMP-1 activity control comprising reduced low-molecular-weight thiols and oxidizing radicals. Journal of Molecular Medicine 2009, 87:261-272.
33. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nature Reviews. Cancer 2011, 11:325-337.
34. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:12072-12077.
35. Lin C.H., Lin P.H. Induction of ROS formation, poly(ADP-ribose) polymerase-1 activation, and cell death by PCB126 and PCB153 in human T47D and MDA-MB-231 breast cancer cells. Chemico-Biological Interactions 2006, 162:181-194.
36. Lisanti M.P., Scherer P.E., Vidugiriene J., Tang Z., Hermanowski-Vosatka A., Tu Y.H., et al. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: Implications for human disease. The Journal of Cell Biology 1994, 126:111-126.
37. Loeffler M., Kruger J.A., Niethammer A.G., Reisfeld R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. The Journal of Clinical Investigation 2006, 116:1955-1962.
38. Martinez-Outschoorn U.E., Balliet R.M., Rivadeneira D.B., Chiavarina B., Pavlides S., Wang C., et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010, 9:3256-3276.
39. Martinez-Outschoorn U.E., Goldberg A., Lin Z., Ko Y.H., Flomenberg N., Wang C., et al. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biology & Therapy 2011, 12:924-938.
40. Martinez-Outschoorn U.E., Lin Z., Ko Y.H., Goldberg A.F., Flomenberg N., Wang C., et al. Understanding the metabolic basis of drug resistance: Therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle 2011, 10:2521-2528.
41. Martinez-Outschoorn U.E., Lin Z., Trimmer C., Flomenberg N., Wang C., Pavlides S., et al. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: Implications for PET imaging of human tumors. Cell Cycle 2011, 10:2504-2520.
42. Martinez-Outschoorn U.E., Pavlides S., Whitaker-Menezes D., Daumer K.M., Milliman J.N., Chiavarina B., et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010, 9:2423-2433.
43. Martinez-Outschoorn U.E., Trimmer C., Lin Z., Whitaker-Menezes D., Chiavarina B., Zhou J., et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 2010, 9:3515-3533.
44. Marumo T., Schini-Kerth V.B., Fisslthaler B., Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 1997, 96:2361-2367.
45. Meng D., Lv D.D., Fang J. Insulin-like growth factor-I induces reactive oxygen species production and cell migration through Nox4 and Rac1 in vascular smooth muscle cells. Cardiovascular Research 2008, 80:299-308.
46. Neumann C.A., Cao J., Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle 2009, 8:4072-4078.
47. Neumann C.A., Krause D.S., Carman C.V., Das S., Dubey D.P., Abraham J.L., et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003, 424:561-565.
48. Nguyen A., Chang A.C., Reddel R.R. Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. Oncogene 2009, 28:1982-1992.
49. Nishikawa M., Hyoudou K., Kobayashi Y., Umeyama Y., Takakura Y., Hashida M. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. Journal of Controlled Release 2005, 109:101-107.
50. Noh E.M., Lee Y.R., Chay K.O., Chung E.Y., Jung S.H., Kim J.S., et al. Estrogen receptor alpha induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells. Molecular Medicine Reports 2011, 4:215-219.
51. Parrinello S., Coppe J.P., Krtolica A., Campisi J. Stromal-epithelial interactions in aging and cancer: Senescent fibroblasts alter epithelial cell differentiation. Journal of Cell Science 2005, 118:485-496.
52. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A.K., Frank P.G., et al. The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.
53. Pezzotti A., Kraft P., Hankinson S.E., Hunter D.J., Buring J., Cox D.G. The mitochondrial A10398G polymorphism, interaction with alcohol consumption, and breast cancer risk. PLoS One 2009, 4:e5356.
54. Provenzano P.P., Inman D.R., Eliceiri K.W., Knittel J.G., Yan L., Rueden C.T., et al. Collagen density promotes mammary tumor initiation and progression. BMC Medicine 2008, 6:11.
55. Radisky D.C., Levy D.D., Littlepage L.E., Liu H., Nelson C.M., Fata J.E., et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 436:123-127.
56. Rohan T.E., Wong L.J., Wang T., Haines J., Kabat G.C. Do alterations in mitochondrial DNA play a role in breast carcinogenesis?. Journal of Oncology 2010, 604304.
57. Russillo M., Di Benedetto A., Metro G., Ferretti G., Papaldo P., Cognetti F., et al. Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: Is it worthwhile?. Journal of Clinical Oncology 2011, 29:2834-2835. author reply 2835.
58. Sampson N., Koziel R., Zenzmaier C., Bubendorf L., Plas E., Jansen-Durr P., et al. ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Molecular Endocrinology 2011, 25:503-515.
59. Sappino A.P., Skalli O., Jackson B., Schurch W., Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. International Journal of Cancer 1988, 41:707-712.
60. Sharpless N.E., Ramsey M.R., Balasubramanian P., Castrillon D.H., DePinho R.A. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 2004, 23:379-385.
61. Shen J., Platek M., Mahasneh A., Ambrosone C.B., Zhao H. Mitochondrial copy number and risk of breast cancer: A pilot study. Mitochondrion 2010, 10:62-68.
62. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012, 62:10-29.
63. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of Clinical Investigation 2008, 118:3930-3942.
64. Sotgia F., Martinez-Outschoorn U.E., Howell A., Pestell R.G., Pavlides S., Lisanti M.P. Caveolin-1 and cancer metabolism in the tumor microenvironment: Markers, models, and mechanisms. Annual Review of Pathology 2012, 7:423-467.
65. Sotgia F., Martinez-Outschoorn U.E., Lisanti M.P. Mitochondrial oxidative stress drives tumor progression and metastasis: Should we use antioxidants as a key component of cancer treatment and prevention?. BMC Medicine 2011, 9:62.
66. 2 level in exhaled breath condensate in primary breast cancer patients. Journal of Cancer Research and Clinical Oncology 2010, 136:923-930.
67. Suda T., Oba H., Takei H., Kurosumi M., Hayashi S., Yamaguchi Y. ER-activating ability of breast cancer stromal fibroblasts is regulated independently of alteration of TP53 and PTEN tumor suppressor genes. Biochemical and Biophysical Research Communications 2012, 428:259-263.
68. Taddei M.L., Giannoni E., Raugei G., Scacco S., Sardanelli A.M., Papa S., et al. Mitochondrial oxidative stress due to complex I dysfunction promotes fibroblast activation and melanoma cell invasiveness. Journal of Signal Transduction 2012, 2012:684592.
69. Tanic N., Milovanovic Z., Dzodic R., Juranic Z., Susnjar S., Plesinac-Karapandzic V., et al. The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. Cancer Biology & Therapy 2012, 13:1165-1174.
70. Tobar N., Guerrero J., Smith P.C., Martinez J. NOX4-dependent ROS production by stromal mammary cells modulates epithelial MCF-7 cell migration. British Journal of Cancer 2010, 103:1040-1047.
71. Toullec A., Gerald D., Despouy G., Bourachot B., Cardon M., Lefort S., et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Molecular Medicine 2010, 2:211-230.
72. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
73. Trimmer C., Sotgia F., Whitaker-Menezes D., Balliet R.M., Eaton G., Martinez-Outschoorn U.E., et al. Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: A new genetically tractable model for human cancer associated fibroblasts. Cancer Biology & Therapy 2011, 11:383-394.
74. Waghray M., Cui Z., Horowitz J.C., Subramanian I.M., Martinez F.J., Toews G.B., et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. The FASEB Journal 2005, 19:854-856.
75. Weitzman J.B. p16(Ink4a) and p19(Arf): Terrible twins. Trends in Molecular Medicine 2001, 7:489.
76. Whitaker-Menezes D., Martinez-Outschoorn U.E., Flomenberg N., Birbe R.C., Witkiewicz A.K., Howell A., et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: Visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011, 10:4047-4064.
77. Whitaker-Menezes D., Martinez-Outschoorn U.E., Lin Z., Ertel A., Flomenberg N., Witkiewicz A.K., et al. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011, 10:1772-1783.
78. Witkiewicz A.K., Dasgupta A., Sammons S., Er O., Potoczek M.B., Guiles F., et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biology & Therapy 2010, 10:135-143.
79. Witkiewicz A.K., Kline J., Queenan M., Brody J.R., Tsirigos A., Bilal E., et al. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle 2011, 10:1794-1809.
80. Witkiewicz A.K., Whitaker-Menezes D., Dasgupta A., Philp N.J., Lin Z., Gandara R., et al. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: Stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012, 11:1108-1117.